Ultragenyx Pharmaceutical RARE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$608.92M-10.9% | -$574.92M-1.0% | -$579.57M-3.6% | -$532.67M+9.0% | -$549.32M+10.5% | ||
| $34M-6.0% | $35M-2.8% | $35.75M+3.1% | $35.9M+8.4% | $36.16M+22.1% | ||
| -$497M-27.7% | -$466M-12.6% | -$445.49M-6.4% | -$421.06M+10.3% | -$389.27M+23.5% | ||
| $6M+25.3% | $6M-14.3% | $5.23M-36.0% | $5.56M-45.7% | $4.79M-78.4% | ||
| —— | —— | —— | —— | —— | ||
| $50M— | $252M— | —— | —— | —— | ||
| -$503M-27.6% | -$472M-12.1% | -$450.71M-5.6% | -$426.62M+11.1% | -$394.06M+25.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ultragenyx Pharmaceutical generate?
- Ultragenyx Pharmaceutical (RARE) generated -$497.0M in operating cash flow over the trailing twelve months.
- What is Ultragenyx Pharmaceutical's free cash flow?
- After $6.0M of capital expenditures, Ultragenyx Pharmaceutical's free cash flow was -$503.0M over the trailing twelve months, down 27.6% year over year.
- Where does Ultragenyx Pharmaceutical's cash flow data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
